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The main input to the basal ganglia, the corticostriatal pathway, shows some
of the earliest signs of neuropathology in Huntington’s disease (HD), an inherited
neurodegenerative condition that typically strikes in mid-life with progressively
deteriorating cognitive, emotional, and motor symptoms. Although an effective treatment
remains elusive, research on transgenic animal models has implicated dysregulation of
glutamate (Glu), the excitatory amino acid released by corticostriatal neurons, in HD
onset. Abnormalities in the control of Glu transmission at the level of postsynaptic
receptors and Glu transport proteins play a critical role in the loss of information
flow through downstream circuits that set the stage for the HD behavioral phenotype.
Parallel but less-well characterized changes in dopamine (DA), a key modulator of
Glu activation, ensure further deficits in neuronal communication throughout the basal
ganglia. Continued analysis of corticostriatal Glu transmission and its modulation by DA,
including analysis at the neurobehavioral level in transgenic models, is likely to be an
effective strategy in the pursuit of HD therapeutics.
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INTRODUCTION
Aberrant function of basal ganglia circuitry plays an important role in multiple neuropathological
conditions (Reiner, 2010). Here we focus onHuntington’s disease (HD), a dominantly inherited and
ultimately fatal neurodegenerative disorder characterized by near-total loss of cognitive, emotional,
and motor control (Cepeda et al., 2007; Zuccato et al., 2010). Early signs of HD neuropathology
emerge in the striatum, the main input structure of the basal ganglia, and the cerebral cortex,
which supplies the striatum with the associative, limbic, and motor information necessary to select
and guide appropriate behavioral responses despite widely varying circumstances and contexts
(Kreitzer and Malenka, 2008; Milnerwood and Raymond, 2010). In effect, the corticostriatal system
supports the production of skilled yet flexible behavioral actions that define a healthy life. HD
disrupts this system by interfering with the mechanisms by which cortical and striatal neurons
communicate.
SYMPTOMS AND NEUROPATHOLOGY OF HUNTINGTON’S
DISEASE
HD afflicts approximately 1 in 10,000 persons of European descent. Other populations are also
affected but at a slightly lower incidence (Harper, 2001; Rawlins et al., 2016). The largest and
best characterized population with HD is localized to the region of lake Maracaibo, Venezuela.
In fact, it was with this population the underlying genetic cause was discovered (Gusella et al., 1983).
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HD is caused by an expansion of the polyglutamine
(CAG) repeat in the huntingtin (htt) gene located on exon 1
of chromosome 4 (The Huntington’s Disease Collaborative
Research Group, 1993), which encodes the protein huntingtin
(HTT). In healthy individuals, htt alleles contain 6–30 CAG
repeats; more than 30 repeats and the gene is consideredmutated.
An expansion of 36 or more CAG repeats will result in disease
onset with full penetrance occurring at 40 or more repeats
(Rubinsztein et al., 1996). An intermediate number of repeats
(e.g., 30–36) is associated with germline instability and can
lead to de novo HD, indicating a higher prevalence of HD
in general populations with longer CAG repeats (Bates et al.,
2015). Although there is considerable variability, the onset and
severity of symptoms is inversely correlated with the number
of CAG repeats; the greater the CAG expansion, the earlier the
onset of symptoms (Nørremølle et al., 1993; Harper and Jones,
2002; Kumar et al., 2010). Symptoms typically begin to manifest
around midlife, 35–45 years of age, with the majority of patients
having between 40 and 50 CAG repeats. An expansion greater
than 50 CAG repeats results in juvenile onset (Telenius et al.,
1993).
Following clinical diagnosis, usually triggered by motor
symptom onset, HD is fatal within 15–20 years. During the initial
stages of the disorder, HD patients experience cognitive deficits
in mood, attention, procedural memory and executive functions
(Lemiere et al., 2004; Estrada-Sánchez et al., 2015a). They also
experience mild motor abnormalities such as tremor or tics.
Following these mild changes, a hyperkinetic stage emerges.
Motor abnormalities, primarly chorea, the defining feature
of HD, manifests with abrupt and uncontrolled exaggeration
of gestures and spontaneous movements of the trunk, face,
and limbs. These movements cannot be volunatrly suppressed
and worsen during periods of heighted stress (Kremer, 2001).
Motor skills continue to deteriorate affecting gait, speech and
swallowing. During this time patients also suffer dramatic weight
loss and muscle wasting despite maintaining a high caloric diet
(Estrada-Sánchez et al., 2015a). Eventually choreic movements
are replaced by bradykinesia and rigidity and ultimately results
in death primarily due to pneumonia and heart disease (Estrada-
Sánchez and Rebec, 2012).
Neuropathological features of HD include: reduced brain
weight, enlarged lateral ventricles, and decreased striatal
and cortical volume. The gross atrophy of the caudate-
putamen (striatum) results mainly from loss of medium
spiny neurons (MSNs), which account for >90% of the
striatal neuronal population. Striatal neuronal loss is usually
accompanied by loss of cortical pyramidal neurons (CPNs),
primarily in motor and premotor areas (Aylward et al.,
1998; Rosas et al., 2001; Menalled et al., 2002). Because
CPN targets include MSNs, the degeneration and loss of
these neurons indicate impaired corticostriatal connectivity
and dysfunctional information processing (Hamilton et al.,
2003; Miller et al., 2011; Estrada-Sánchez and Rebec, 2012).
Thus, although mutant HTT is widely expressed in brain
and body, primary neuropathology occurs in the cerebral
cortex and the striatum. This review will focus on changes in
corticostriatal circuitry and how glutamate (Glu), the transmitter
released by CPNs, and its interaction with dopamine (DA),
a key modulator of striatal function, affect this circuitry in
HD. Multiple animal models of HD developed soon after
identification of the htt gene form the basis for this line of
research.
ANIMAL MODELS
A few years following identification of the gene, transgenic
rodent models were developed in order to investigate
mechanisms underlying the HD phenotype. Genetic murine
models can be separated into three groups: transgenic truncated
models, transgenic full-length models, or knock-in (KI) models.
Truncated models solely express the first exon of the htt gene,
where the CAG expansion occurs. Full-length models express
the entire human mutant htt gene. Both of these transgenic
models contain two non-mutated endogenous htt alleles making
the mutant HTT to HTT ratio differ from that seen in humans.
This raises translational concerns as some cellular alteration in
the truncated and full-length models may not be an accurate
reflection of the human condition. KI models avoid this
translational confound by directly inserting the CAG expansion
into exon 1 of the endogenous htt gene; thereby mirroring the
genetic construct of HD patients.
Truncated Models
The truncated R6 line is the oldest and one of the most studied
transgenic mouse models. R6/2 mice, with a CAG repeat length
of ∼150, have an aggressive phenotype. R6/2 mice have a
shortened lifespan of 3–5 months with symptom onset beginning
as early as 1 month of age (Mangiarini et al., 1996). R6/1 mice
have a longer life expectancy than R6/2 mice. With 110 to 115
CAG repeats, R6/1 mice become symptomatic between 4 to
5 months with more robust motor symptoms emerging around
6 to 7 months of age followed by death at 10 to 14 months
(Mangiarini et al., 1996; Naver et al., 2003).
The R6 line has neuronal intracellular and intranuclear
aggregates contacting the mutant HTT fragment (Davies et al.,
1997); as well as reduced striatal volume (Stack et al., 2005).
Motor deficits including tremor, reduced climbing, and clasping
has been observed in R6 truncated models (Mangiarini et al.,
1996; Miller et al., 2008). Susceptibility to epileptic seizures
(Mangiarini et al., 1996) and decreased learning has also been
observed in these truncated models (Murphy et al., 2000). These
behavioral changes are correlated to neurochemical changes in
basal ganglia circuitry (Bibb et al., 2000; Ariano et al., 2002;
Johnson et al., 2006; Miller et al., 2008; Ortiz et al., 2010).
Full-Length Models
Two full-length transgenic HD models have been developed:
the yeast artificial chromosome (YAC) and bacteria artificial
chromosome (BAC). Several lines of the YACmouse model have
been generated based on the number of CAG repeats:
YAC18 (control), YAC46, YAC72, and YAC128. Compared to
truncated models, YAC and BAC mice have a slower disease
progression. As is the case with humans, the YAC128 mouse
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model displays striatal followed by cortical atrophy as well
as hyperkinetic followed by hypokinetic activity in an age-
dependent manner (Slow et al., 2003; Van Raamsdonk et al.,
2005). The BAC model, which carries 97 CAA-CAG repeats,
also exhibits a progression motor deficits, decreased striatal
and cortical volume, and decreased MSN synaptic activity
(Gray et al., 2008). BACHD mice have also shown abnormal
striatal and cortical firing patterns (Estrada-Sánchez et al.,
2015b).
The YAC128mousemodel is one of the few transgenicmodels
exhibiting both the hyper- and hypoactive phenotype seen in
humans as well as striatal followed by cortical atrophy (Slow
et al., 2003; Van Raamsdonk et al., 2005). In the YAC128 mouse
model, by 3 months of age a hyperkinetic phenotype emerges this
is then followed by progressive motor deficits. By 9 months of
age, motor deficits are apparent and the hypokinetic phenotype
is accompanied by striatal atrophy; when the animal reaches
12 months of age cortical atrophy also starts to occur (Slow et al.,
2003). Because the onset of symptoms does not occur as rapidly
in the YAC128 model as truncated models; initial symptoms
seen in humans as well as neurochemical changes throughout the
progression of this biphasic (hyper- and hypo-) active disorder
can be studied in more depth.
Knock-in Models
Multiple HD KI models have been created. KI models carry
the expanded CAG repeats within the native murine htt gene,
closely mimicking the genetic context of patients with HD. KI
models provide stronger construct validity compared to other
transgenic rodent models. However the protracted phenotype
observed in KI models has limited their use. Current KI mouse
models show subtle behavioral, histopathological, and molecular
phenotypes compared to the transgenic models that over express
mutant HTT (truncated and full-length models; Chang et al.,
2015). The CAG140 KI mouse model has a normal lifespan,
with overt symptoms emerging after 20 months of age (Hickey
et al., 2008). CAG140 mice do have the characteristic nuclear
aggregates and decreased striatal volume seen in other models
(Menalled et al., 2003; Hickey et al., 2008). The Q175 KI
model was derived by a spontaneous germline CAG expansion
from the previously constructed CAG140 KI mouse model
(Menalled et al., 2012). Initial characterization of this new
mouse model showed decreased body weight, body tremor,
abnormal gait, and activity level. Decreased striatal and cortical
volume has also been observed along with decreased cognitive
ability (Heikkinen et al., 2012; Menalled et al., 2012). These
behavioral changes observed in HD KI models mirror changes
seen other mouse models and HD patients (Mangiarini et al.,
1996; Slow et al., 2003; Miller et al., 2011; Estrada-Sánchez et al.,
2015a).
CORTICOSTRIATAL PATHWAY OVERVIEW
As the primary input nucleus of the basal ganglia, the striatum
receives excitatory afferents from the entire cortical mantel as
well as the thalamus (Kreitzer and Malenka, 2008). Because
the primary neuropathology of HD involves the loss of MSNs
and CPNs, the HD behavioral phenotype is likely due to
dysfunction of the cortical-basal ganglia system. Therefore a
greater understanding of the corticostriatal pathway and its
activity is necessary for a fuller understanding of both HD
pathology and behavioral phenotype.
Cortex
In humans, the cortical mantel is divided into six layers with
astrocytes homogenously distributed throughout. The different
types of cortical neuronsmake local cortical connections between
cells of different layers as well as send and receive projections
from other brain regions, such as the striatum. Layer III, V,
and VI all contain CPNs. CPNs from layer III and V are the
primary input to the basal ganglia, brain stem, and spinal cord.
CPNs from layer VI send projection to the thalamus (McGeorge
and Faull, 1989; Shipp, 2007; Estrada-Sánchez and Rebec, 2013).
Post-mortem tissue taken from HD patients has a 30% reduction
in CPNs for these three cortical layers (Cudkowicz and Kowall,
1990; Hedreen et al., 1991; Sotrel et al., 1991; Heinsen et al.,
1994). While the entire cortical mantel projects to the striatum,
this review will be referring to CPNs of the motor cortex due
to the motor cortex’s involvement in execution and control of
voluntary movements. This reduction of CPNs as well as studies
showing dysfunction CPNs neuronal firing (Walker et al., 2008)
potentially underlies the HD behavioral phenotype.
Two types of striatal-projecting CPNs have been identified:
(1) pyramidal tract (PT)-type neurons; and (2) intra-
telencephalically projecting (IT)-type neurons. PT-type neurons
project to ipsilateral striatum, thalamus, and subthalamic
nucleus (STN) as well as the regions of the spinal cord and
brain stem. IT-type neurons project to the ipsilateral and
contralateral striatum and other cortical layers (Shepherd, 2013).
PT-type neurons are mainly found in the lower cortical layer
V and IT-type neurons are primarily located in layer III and
upper half of layer V. The different morphological features and
location of PT- and IT-type neurons suggest these two types of
neurons differentially target striatal MSNs, with IT-type neurons
differentially targeting MSN of the direct pathway and PT-type
neurons preferentially innervate MSNs of the indirect pathway
(Reiner et al., 2003; Parent and Parent, 2006; Chen et al., 2013).
Striatum
MSNs are GABAergic neurons that constitute 95% of the
neuronal population of the striatum. Interneurons in the
striatum are also primarily GABAergic, with some cholinergic
interneurons (Kreitzer and Malenka, 2008). There are two major
subtypes of striatal MSNs based on their protein expression
and their axonal projections: (1) Striatonigral MSNs express
substance P (subst P), dynorphin, and D1-like DA receptors.
They project directly to the basal ganglia output nuclei: internal
globus pallidus (GPi) and substantia nigra pars reticulata (SNr);
and (2) Striatopallidal MSNs contain enkephalin (enk) and
express D2-like DA receptors. Striatopallidal MSNs projects
to the external globus pallidus (GPe) and are part of the
indirect pathway. Both striatonigral and striatopallidal MSNs
integrate glutamatergic cortical and thalamic inputs and relay
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that information to downstream basal ganglia nuclei (Kreitzer
and Malenka, 2008).
These two subtypes of MSNs have been used to segregate
basal ganglia circuitry into two pathways: the direct pathway
containing striatonigral D1-enriched MSNs and the indirect
pathway containing striatopallidal D2-enriched MSNs. These
pathways are believed to act in opposing ways to control
movement. According to this view, the direct pathway, which
consists of the striatonigral MSNs, initiates movement; whereas,
the indirect pathway, consisting of striatopallidal MSNs, inhibits
movement (Alexander and Crutcher, 1990). While these
pathways are not completely isolated (Haber et al., 2000; Cui
et al., 2013), for simplicity, we will discuss them as parallel
circuits, depicted schematically in Figure 1.
The direct pathway is thought to facilitate movement (Albin
et al., 1989; DeLong, 1990). Striatonigral MSNs in the striatum
receive excitatory, glutamatergic projections from the cortex and
thalamus. This results in excitation of the striatal GABAergic
MSNs, which in turn inhibits the GABAergic projection in the
GPi/SNr. The inhibition of the inhibitory GABAergic neurons
in the GPi/SNr results in less inhibition on the thalamus
glutamatergic neurons. This results in excitation of the motor
cortex and initiation of voluntary movement. By this schematic,
dysregulation of striatonigral MSN projection neurons would
result in rigidity and bradykinesias.
The indirect pathway is presumed to inhibit movement
(Albin et al., 1989; DeLong, 1990; Durieus et al., 2009;
FIGURE 1 | Simplified schematic representation of basal ganglia
circuitry highlighting cortical and striatal outputs. Open arrows represent
excitation, closed arrows represent inhibition. Neurotransmitters are indicated
in parenthesis. Intra-telencephalically projecting (IT)-type CPNs project to the
striatongiral D1-enriched MSNs of the direct pathway. Pyramidal tract
(PT)-type CPNs project to the stratopallidal D2-enriched MSNs of the indirect
pathway. Abbreviations: Glu, glutamate; enk, enkephalin; subst P,
substance P.
Kravitz et al., 2010). Striatopallidal MSNs inhibit GABAergic
neurons in the GPe. This in turn results in less inhibition on
the glutamatergic projection in the STN. The glutamatergic
projections from the STN excite the GABAergic neurons in the
GPi/SNr which results in greater inhibition to the thalamus
and decreased signaling to the motor cortex (Alexander and
Crutcher, 1990). Thus dysregulation of MSNs in the indirect
pathway result in uncontrollable voluntary movements, such as
chorea and tremor (Bateup et al., 2010).
Glu projections from the cortex are not the only influence
on basal ganglia circuitry. DA projections from the substantia
nigra pars compacta (SNc) play a modulatory role. Evidence
suggests D1-like receptor signaling facilitates glutamatergic
signaling in direct pathway, striatonigral MSNs. In contrast, D2-
like receptor activation inhibits MSNs in the indirect pathway
(Figure 1; Surmeier et al., 2007). Therefore DA projections
from the SNc results in excitation (D1-like) or inhibition (D2-
like) of the direct or indirect pathway, respectively, the ultimate
results is facilitation of movement. Therefore a dysregulation
of Glu or DA, which modify the excitatory responses induced
by Glu (Kiyatkin and Rebec, 1999; Cepeda and Levine,
2006), could results in uncontrolled involuntary movements or
bradykinesia.
DYSREGULATION OF THE
CORTICOSTRIATAL PATHWAY
Motor function is in part shaped by CPNs projecting to striatal
MSNs in the so-called corticostriatal pathway. The cerebral
cortex and striatum are the most affected brain areas in HD,
with massive MSN loss in the striatum. Not all MSNs however
are equally vulnerable (Vonsattel and DiFiglia, 1998; Galvan
et al., 2012). Morphological evidence shows time-dependent,
differential alterations in the two populations of MSNs. MSN
in the indirect pathway tend to be preferentially lost prior to
MSN in the direct pathway. Evaluation of indirect striatopallidal
MSNs and their projections (i.e., enk) are lost in postmortem
tissue of symptomatic patients and in presymptomatic and early
symptomatic brains of HD mouse models. In contrast, direct
striatonigral MSNs projecting subst P are not as greatly affected
and in some cases appear unaffected till later, advance stages of
the disease (Albin et al., 1992; Sapp et al., 1995; Menalled et al.,
2000).
In keeping with the direct/indirect model of basal ganglia
movement control, the preferential loss of MSN in the indirect
pathway can result in the inability to control voluntary
movement, resulting in a hyperkinetic phenotype (chorea).
The dysfunction of the direct pathway in the later stage
of the disease would result in an inability to facilitate
movement; resulting in a rigidity and bradykinesia (see above).
Thus changes in output from striatal MSNs, which receives
Glu input from the cortex, correlates with the behavioral
phenotype of HD.
Particular focus has been placed on the neuronal activity of
the cortex and striatum. Regardless of genetic construct and
phenotypic onset, changes ranging frommembrane properties to
impaired neuronal processing in the corticostriatal pathway have
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been identified in multiple mouse models of HD (Walker et al.,
2008; Miller et al., 2011; Heikkinen et al., 2012; Estrada-Sánchez
et al., 2015a,b). Abnormal MSN activity has been observed
in presymptomatic and symptomatic transgenic mouse models
(Rebec et al., 2006; Miller et al., 2008, 2011; Cayzac et al.,
2011; Estrada-Sánchez et al., 2015b). Abnormal CPN activity
has also been observed in HD mouse models (Walker et al.,
2008, 2011). Multiple transgenic mouse models show increased
firing rate with decreased burst firing and firing variability in
the dorsal striatum and primary motor cortex. A decrease in
synchronous firing and coherent bursting was also observed in
the cortex and striatum of transgenic murine models (Walker
et al., 2008; Höhn et al., 2011; Miller et al., 2011; Estrada-
Sánchez et al., 2015b). Changes in neuronal activity level and
variability along with changes in burst firing, which is involved
in synaptic plasticity and enhanced information transmission,
demonstrate neuronal dysfunction in the striatum and cortex
thereby indicating a communication problem between the cortex
and dorsal striatum.
In vitro electrophysiology analysis showed resting membrane
potential of MSNs are more depolarized in Q175 mice as
well as show significantly less rheobasic current (the minimum
current amplitude that results in depolarization) in HOM mice
(Heikkinen et al., 2012), indicating Q175 striatal MSNs become
progressively excitable and abnormal corticostriatal neuronal
activity emerges as the animals age. Collectively, these studies
suggest that dysregulation of MSN firing patterns are a cardinal
feature of HD.
Besides abnormal electrophysiological properties of CPN
and MSN, dysfunctional network activity has been described
both in HD patients and HD models. Neurons operate in a
coordinated way and large neuronal population activity can
be monitored by local field potentials (LFPs). Spectral analysis
of LFPs recorded from the striatum of freely behaving R6/2
mice revealed an increase in power in theta (7–14 Hz) and
gamma (35–45 Hz) bands (Miller et al., 2011). Increased power
in theta/alpha (4–12 Hz) and low gamma (35–45 Hz) bands
also has been observed in LFP activity recorded in the globus
pallidus of HD patients (Groiss et al., 2011; Hong et al., 2012).
Thus, expression of mutant HTT cause changes in corticostriatal
processing that may underlie HD cognitive and behavioral
deficits.
Interneurons also may play a role in corticostriatal
dysfunction in HD. GABAergic control of striatal MSNs
comes primarily from feedforward inhibition derived from
local inhibitory interneurons (Tepper et al., 2004). Specifically,
parvalbumin-expressing (PV) fast-fast spiking (FS) GABAergic
interneurons are the main source of this feedforward inhibition
(Gittis et al., 2010). Because PV FS interneurons receive strong
cortical innervation (Ramanathan et al., 2002) and respond with
faster latency to cortical stimulation than MSNs (Mallet et al.,
2005), PV FS cells are able to make feedforward inhibition work
effectively. Furthermore, PV FS interneurons project strongly to
MSNs (Taverna et al., 2007) with a slight targeting preference for
direct-pathway MSNs (Gittis et al., 2010).
In a recent study, significant decreases in striatal PV FS
interneurons were observed in postmortem tissue of HD patients
with varying degrees of atrophy (Reiner et al., 2013). These
changes in interneurons could result in disrupted direct-pathway
MSN communication to the GPi. In HD, therefore, local
inhibition on the subst P-containing striatonigral D1-enriched
MSNs (direct pathway) is limited. According to the highly
schematic and simplified circuitry shown in Figure 1, decreased
inhibition on the direct pathway would result in more GABA
release in GPi, less GABA release in thalamus, and thus more
excitation of motor cortex.
Increased firing of FS interneurons has also been observed in
HD mouse models. For example, increased GABAergic synaptic
activity in symptomatic HD mouse models was observed,
primarily from feedforward inhibition of indirect pathway
MSNs (Cepeda et al., 2013). Thus, an increase in activity in
the indirect pathway from striatum would result in decreased
movement during the later stages of HD. In short, inhibitory
interneurons act locally in dorsal striatum to influence basal
ganglia output.
GLUTAMATE IN HUNTINGTON’S DISEASE
Pioneering studies by Wong et al. (1982) demonstrate
perturbation in the synthesis of Glu by corticostriatal neurons.
Since then further investigation into Glu receptors and Glu
uptake have been investigated in relation to deviations in the
corticostriatal pathway.
One major hypothesis is that excitotoxicity underlies striatal
neurodegeneration in HD (DiFiglia, 1990). Excitotoxicity can
be a result from: (1) an increase in responsiveness of Glu
receptors; or (2) an increase in synaptic Glu. The responsiveness
of Glu receptors can change due to either an increase in the
number of receptors or receptor density or a change in receptor
composition or signaling properties. An increase in synaptic Glu
could be due to an increase in release or a decrease in uptake. The
literature primarily focuses on N-methyl-D-aspartate (NMDA)
receptors and removal of excess Glu via glutamate transporter 1
(GLT1).
NMDA Receptors in HD
NMDA receptors are ionotropic Glu receptors that serve as
essential mediators of neuronal function, synaptic transmission,
synaptic plasticity, and aspects of neural development (Purves
et al., 2008; Iversen et al., 2009). In HD degeneration of
MSNs occurs, and while the mechanism behind this selective
degeneration is not well understood, convergent evidence
supports the role for NMDA receptor mediated excitotoxicity
(Beal et al., 1986; Ferrante et al., 1993; Cepeda et al., 2007; Fan
and Raymond, 2007).
Striatal injections of NMDA receptor agonists in rodent and
non-human primates reproduce the pattern of neuronal
damage seen in HD (Beal et al., 1986; Ferrante et al.,
1993). Furthermore electrophysiological assessment of pre-
symptomatic and symptomatic R6/2 mice found larger NMDA
currents and NMDA-induced Ca2+ influx compared to
littermate controls (Cepeda et al., 2001). It was speculated
the striatal neuronal subpopulation that displayed the most
elevated response to NMDA application corresponded to
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indirect MSNs. The increase in NMDA response as well as
enhancement of intracellular calcium suggests changes in
NMDA receptors signaling could result in excitotoxicity and
neuronal death.
NMDA exposure to the MSNs cultured cells resulted in
a potentiation in apoptosis of YAC72 and YAC128 MSNs
compared to the healthy YAC18 control MSNs. Moreover
producing a reduction in NMDA receptor mediated current and
calcium influx in YAC72 MSNs to levels seen in YAC18 MSNs
resulted in a reduction of NMDA receptor-mediated apoptosis
(Shehadeh et al., 2006). Thus, controlling NMDA signaling
brought the rate of apoptosis in HD mice to a comparable level
seen in WT controls.
However NMDA receptor activation has been shown to
promote both neuronal cell survival as well as neuronal
cell death (Hardingham and Bading, 2010). Synaptic NMDA
receptor activity has been shown to reduce mhtt toxicity and
act as a neuroprotectant while extrasynaptic NMDA receptors
have been associated with promoting cell death (Okamoto
et al., 2009; Milnerwood et al., 2010). Okamoto et al. (2009)
found synaptic NMDA receptor activity reduces mutant htt
toxicity by increasing the formation of non-toxic mutant
htt inclusions by a process involving the up-regulation of
protein chaperones thereby rendering neurons more resistant
to mhtt-mediated cell death. In contrast, stimulation of
extrasynaptic NMDA receptors increased the vulnerability of
neurons to cell death by impairing a neuroprotective CREB-
PGC-1α cascade. Furthermore treatment with lower doses
of memantine, which blocks extrasynaptic but not synaptic
NMDA receptors, improves neuropathological and behavioral
manifestations of HD (Okamoto et al., 2009). Also pre-
symptomatic YAC128 mice treated at a low level dose that
preferentially targets extrasynaptic NMDA receptors resulted
in reversal of early signaling and motor deficits (Milnerwood
et al., 2010). Though at higher doses, when memantine also
blocks synaptic NMDA receptors, memantine worsened the
manifestation of HD (Okamoto et al., 2009). This perturbation in
the balance between synaptic NMDA and extrasynaptic NMDA
receptor activity could contribute to excitotoxicity and neuronal
dysfunction in HD.
Glutamate Uptake in HD
Inadequate Glu uptake has been reported for HD patients
as well as transgenic mouse models of HD. The removal of
Glu from the synaptic cleft is controlled by several transport
proteins; including: GLT1, L-glutamate/L-aspartate transporter
(GLAST), and excitatory amino-acid carrier 1 (EAAC1). Note
GLT1 is also known as in EAAT2 in humans and is primarily
located on glial cells. Glu transporters play a vital role in
maintaining the level of extracellular Glu by removing Glu from
the synapse; dysregulation of this Glu uptake can result in slow
Glu clearance prompting Glu spillover and increased receptor
activation (Beart and O’Shea, 2007; Estrada-Sánchez et al., 2008).
These high concentrations of Glu can result in excitotoxicity,
a pathological process in which neuronal cells are damaged or
killed due to excessive stimulation. Therefore the functionality
of the Glu transporters plays a critical role in preserving the
local integrity of excitatory synaptic transmission (Marcaggi and
Attwell, 2004).
Astrocytes not only play a role in Glu uptake via Glu
transporters, but recent evidence indicates that mutant htt can
affect astrocytes in a way that increases Glu release and MSN
excitability (Lee et al., 2013; Khakh and Sofroniew, 2014; Tong
et al., 2014). Calcium and Glu imaging of astrocytes in the
full-length BACHD mouse model showed increased release
of Glu into extracellular space. Furthermore BACHD mice
have increased de novo synthesis of Glu (Lee et al., 2013).
This ability of mutant htt to increase Glu production and
release could further contribute to the excitotoxicity seen in
HD. Additionally, a reduction in astrocyte functional proteins,
including GLT1and Kir4.1, has been associated with onset
of neurological symptoms (Tong et al., 2014). Restoration of
Kir4.1 channels through viral vector administration attenuated
MSN excitability, improved gait, and increased the lifespan
of HD mice (Khakh and Sofroniew, 2014; Tong et al.,
2014). For a more thorough review of astrocytes involvement
in circuitry and disease models, see Khakh and Sofroniew
(2015).
GLT1 is responsible for 90% of extracellular Glu uptake and
is either down regulated or dysfunctional in HD mouse models
(Estrada-Sánchez and Rebec, 2012). Although the extracellular
concentration of Glu is similar in HD mice to that of WT
controls (NicNiocaill et al., 2001; Gianfriddo et al., 2004), the
length of time Glu remains in the synapse is prolonged in
HD models. A microdialysis study found Glu release is larger
and takes longer to return to basal levels in the striatum of
R6/1 mice (NicNiocaill et al., 2001), indicating a change in
Glu uptake. Moreover, Lievens et al. (2001) showed a decrease
of GLT1 mRNA in the striatum and cortex of R6/2 mice
accompanied by a concomitant decrease in Glu uptake without
a change in GLAST and EAAC1. Other studies have confirmed
the decrease in GLT1 protein (Estrada-Sánchez et al., 2009, 2010;
Sari et al., 2010), but some of these studies also found a decrease
GLAST (Estrada-Sánchez et al., 2009, 2010). A study using the
CAG140 KI mouse model found functional changes in EAAC1,
but the overall protein level of EAAC1 in HD mice was not
significantly different from the level in WT controls (Li et al.,
2010). Thus, not only is Glu uptake decreased, suggesting a
functional change, but expression of the Glu transporter proteins,
especially GLT1, is also decreased, indicating an underlying
change in the uptake machinery itself. Further discussion of this
machinery and the Glu synapse, including the role of astrocytes
in Glu regulation, is described elsewhere (Estrada-Sánchez et al.,
2015a).
Because the experiments using the R6 mouse models
were carried out before the overt neurological phenotype
emerged, the down-regulation of GLT1 appears to persist
throughout the progression of HD and is a likely contributor to
neurodegeneration. Furthermore, stimulation of layer V afferents
innervating the striatum evoked excitatory postsynaptic currents
(EPSCs) mediated by Glu. The evoked EPSCs are decreased in
Q175 mice, indicating dysregulation of Glu transmission in this
model (Menalled et al., 2012).
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Dysregulation of Glu also has been observed in human
postmortem studies. In 1986, Cross et al. (1986) studied the
binding of [3H]-aspartic acid to the high-affinity Glu uptake
system and found a significant reduction in [3H]-aspartic acid
binding in both the caudate nucleus and putamen of HD subjects.
A reduction in the transporter GLT1 mRNA was also observed
in the caudate and putamen of HD patients, suggesting a loss
of Glu transporter (Arzberger et al., 1997). In a recent study,
uptake of [3H]-glutamate was reduced by over 50% in the
prefrontal cortex of HD patients with no change in GLAST but
a decrease in EAAT2 (Hassel et al., 2008), further demonstrating
a dysregulation in Glu clearance. Postmortem evaluation of
HD patients revealed a grade-dependent decrease in striatal
GLT1 expression (Faideau et al., 2010). Increasing evidence
implicates deficits in Glu uptake in HD pathology and that this
decrease is, at least in part, due to down regulation of the GLT1
transporter.
Manipulation of GLT1 has been tested as a therapeutic
target. Acute administration of ceftriaxone, a β-lactam antibiotic
known to elevate GLT1 expression (Rothstein et al., 2005),
resulted in attenuation of behavioral deficits. Paw clasping
and twitching were reduced in HD mice compared to WT
control (Miller et al., 2008). These results not only indicated
impaired Glu uptake is a major factor underlying HD
pathophysiology and symptomology, but restoration of GLT1
could be a viable treatment for HD. Furthermore ascorbic
acid, which is associated with GLT1, appears decreased in
HD mice. Following treatment with ceftriaxone, ascorbic acid
was increased in HD mice (Miller et al., 2012). These results
suggest a dysfunction of the Glu system in HD. An increase in
Glu uptake via GLT1 is a viable therapeutic strategy because
it removes excess Glu from the synapse which can result in
excitotoxicity.
DOPAMINE IN HUNTINGTON’S DISEASE
Aberrant DA signaling underlying behavioral abnormalities
in HD was first proposed in 1970 based on evidence that
asymptomatic offspring of individuals with HD developed
dyskinesia following levodopa (L-DOPA) administration
(Klawans et al., 1970). Further studies of HD patients suggest
increased DA release induces chorea while a reduction in DA
leads to akinesia. Levels of DA were found to be 11-fold higher
in the cerebrospinal fluid (CSF) of early-stage HD patients
compared to healthy individuals (Garrett and Soares-da-Silva,
1992), but decreased DA was found in patients studied at a
later stage in the disease (Kish et al., 1987). In line with this
finding, recent work has shown biphasic changes in DA release
in the R6/1 mouse model of HD: enhanced DA release during
pre-symptomatic stages and severely attenuated DA release
in symptomatic animals (Dallérac et al., 2015). Collectively,
these results suggest a biphasic, age-dependent change in DA
transmission in HD.
The progressive reduction in striatal DA levels during later
stages of HD has been confirmed in multiple studies (Hickey
et al., 2002; Johnson et al., 2006; Ortiz et al., 2010, 2011;
Callahan and Abercrombie, 2011; Dallérac et al., 2015), but it
remains unclear if early stages promote DA excess. One study
using transgenic HD rats showed increased striatal tyrosine
hydroxylase expression and increased DA neurons during the
early symptomatic stage (Jahanshahi et al., 2010). These rats,
however, also have been shown to have impaired DA release
(Ortiz et al., 2012). Further work is required to clarify DA
changes during the hyperkinetic stages of HD.
Deficits in DA levels and/or release during late HD stages in
rodent models have been attributed either to impaired vesicle
loading (Suzuki et al., 2001) or to a reduction in the DA
readily releasable pool (Ortiz et al., 2010). In vitro studies of
R6/2 and R6/1 mice have shown a decrease in extracellular DA
concentrations as well as a decrease in DA release (Johnson
et al., 2006) and uptake (Ortiz et al., 2011). The decrease in DA
release emerged during symptom onset and became significant
as the animals aged. Importantly, both R6/2 and R6/1 mice have
late-stage reductions in DA release, but only R6/1 mice have
decreased uptake. Moreover, the decrease in uptake occurred
towards the end of the R6/1 lifespan, suggesting that the R6/2-
R6/1 uptake difference could be explained by the increased
lifespan of the R6/1 model (Mangiarini et al., 1996).
In both HD patients and mouse models, D1 and D2 receptors
are compromised during the early as well as late stages of the
disease (Chen et al., 2013). An autoradiography study found a
decrease in both DA receptor families (Richfield et al., 1991).
Positron emission tomography studies have also found decreased
striatal D1 and D2 receptors in asymptomatic carriers of mutant
htt (Weeks et al., 1996; van Oostrom et al., 2009). Multiple
studies using the R6 line have also found decreased D1 and D2
receptors signaling and receptor binding (Cha et al., 1998; Bibb
et al., 2000; Ariano et al., 2002). A significant reduction in D1
and D2 mRNA was also found in YAC128 mice (Pouladi et al.,
2012). Collectively these studies indicate DA receptors, which
are involved in modulating basal ganglia circuitry, are disrupted
throughout HD progression and in some cases prior to disease
onset.
The traditional, albeit simplified view of basal ganglia
circuitry, proposed behavioral abnormalities in HD are the
result of initial dysregulation of the striatopallidal MSNs of
the D2-enriched indirect pathway, resulting in hyperkinetic
choreic movements. This is then followed by dysregulation of the
striatonigral D1-enriched MSNs of the direct pathways, resulting
in hypokinesia (Spektor et al., 2002). However recent studies
have suggested a counter view, the direct pathway is affected first
by D1 receptor activation. Striatal MSNs receive glutamatergic
inputs modulated by DA (Cepeda and Levine, 2006). Different
DA receptors are localize in different striatal cell populations
with less than 10% of D1 and D2 MSNs co-localized (Deng et al.,
2006; Lobo et al., 2006; Cepeda et al., 2008). This lead to the idea
that DA modulates the direct and indirect pathway by opposing
action, with DA release increasing activity in the direct pathway
and reducing activity in the indirect pathway (see above; DeLong
and Wichmann, 2007).
However it has been difficult to parcel out the exact
mechanism by which D1 and D2 DA receptors influence
the direct and indirect pathway. Recently animal expressing
enhanced green fluorescent protein (GFP) in either D1 or
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D2 receptors have been studied. Using electrophysiology with
these mice a DA receptor-specific modulation of EPSC and
NMDA and AMPA currents was found. D1 receptor agonist
increased EPSC in D1 MSNs projecting to the direct pathway
whereas D2 receptor agonist decreased EPSCs in D2 cells of the
indirect pathway. Changes in NMDA and AMPA current were
also DA receptor-specific. A D1 agonist resulted in increased
current in direct pathway MSNs, and a D2 receptor agonist
resulted in decreased NMDA and AMPA current in the indirect
pathway MSNs (André et al., 2010). Thus Glu receptor-mediated
responses in MSNs are modulated by the type of DA receptor
abundantly expressed in that cell.
Additionally, these results suggest D1 receptor activation
leads to increased Glu receptor response on MSNs in the direct
pathway, which would result in increased GABA release to the
GPi resulting in hyperkinetic movement. An electrophysiological
study testing full-length HD mouse models crossed with mice
expressing enhanced GFP found direct pathway MSNs received
more excitatory inputs than control animals during the early
hyperkinetic stage. The indirect pathway MSNs were not as
affected during this early stage, and during the hypokinetic
stage both pathways received less excitatory inputs compared to
WT controls (André et al., 2011; Galvan et al., 2012). Further
suggesting increased DA in the early stages of HD contributes
to the hyperkinetic symptoms of HD by modifying the direct
pathway first.
Morphological assessments have found the indirect pathway
to be affected initially in HD (see above). Electrophysiological
data from mice expressing GFP now suggest the direct pathway
is affected in the early stages of HD via D1 receptor activation.
More than likely it is a combination of D1 receptor activation in
the direct pathway in conjunction with decreased function of the
indirect pathway. Since both theories would result in increased
GABAergic output to the direct pathway, the ultimate result is an
exacerbated HD phenotype.
CONCLUSION
HD is a multifaceted disorder displaying cognitive, psychiatric,
and motor deficits. The dysregulation in the corticostriatal
pathway contributes to these associated characteristics of HD
and potentially underlie the HD phenotype. Dysregulation of
Glu and DA have been documented in HD patients as well
as rodent models, and the abnormal electrophysiology, due
to these neurotransmitters, further indicates that disrupted
communication in the corticostriatal pathway in HD.
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